Excerpt from 2018 CPhl Annual Report, from article by Bikash Chatterjee, President and CSO, Pharmatech Associates:
“We have seen groundbreaking drug therapies and diagnostics approved in the last five years that position regulatory bodies to embrace these new innovations. Whether risk is managed via enhanced control and oversight--such as with the EUs GDPR legislation-- or is a by-product of intelligently gathered real-world data, as provided under the US’s 21st Century Cures Act, the regulatory evaluation in each framework required to evaluate these new technologies will be grounded in today’s scientific tools and analytic techniques. Technology is playing an increasingly large role in improving rates of attrition. Over the next five years, big data will catalyse drug discovery, with R&D leading to quicker advancement of more targeted therapies” said Chatterjee.
Michele Levenson of Pharmatech Associates writes about risk-based validation in an expert column in Pharmaceutical Online. Depending on where your organization is on the pendulum of risk tolerance, there are many benefits to adopting risk-based validation (RBV) and ASTM E2500 within an overall validation strategy, as long as the organization is structured appropriately.